Koneksa, an evidence-based digital biomarkers company, has announced an extended partnership with SSI Strategy, a life sciences consulting firm, that will provide both organizations with expanded client service offerings to accelerate and scale the adoption of evidence-based digital biomarkers in clinical trials.
Koneksa's digital biomarker solutions include an industry-leading platform that gives research sponsors and clinical sites the ability to seamlessly aggregate data in real-time from devices, ePROs, patient diaries, and clinical assessments to provide the full picture of an individual’s health.
As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drug development. This collaboration will offer existing clients of both organizations a streamlined relationship offering the industry’s best scientific, technical, and delivery expertise across all phases of the clinical trial and product lifecycle. Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drug development. SSI clients gain access to Koneksa's industry-leading expertise in developing and employing evidence-based digital biomarkers.
“This synergistic partnership is a combination of resources, talent and expertise across two leading science-based organizations with a mission of optimizing and accelerating therapies for patients in need, through greater adoption of digital biomarkers in clinical studies,” said Vik Shah, President and COO of Koneksa in a news release. “This expanded partnership is in response to the growing interest from life sciences companies to have an in-house digital biomarker solution, and SSI will enable us to rapidly scale our medical and scientific functions to meet this demand. SSI will also be able to provide clients with leading expertise in digital biomarkers from the Koneksa team, to accelerate clinical trials and bring new life-saving therapies to patients faster.”
“Koneksa’s digital biomarker solutions capture actionable measures that will enable therapeutic developers to efficiently address pre- and post-market evidence requirements at much earlier stages of development,” said Doug Locke, CEO of SSI Strategy. “We particularly see the collaboration as mutually beneficial to many of our rare-disease client partners, in alignment with our growing digital health practice.”
Click here to read the original news story.
Looking for expert insights in Clinical Trials Innovation? Join the HealthXL Masterclass on ‘Design and Control Conditions for Clinical Trials of Digital Health Solutions’ on 29th March. Click here to Request to Join.